In addition, multivariable logistic regression analyses revealed that anti-ENO1 antibody could be used as potential diagnostic biomarker for the identification of patients with NSCLC, AD or SCC after adjustment for age and gender (P<0.05 for all) (Table 3). Here, ENO1 is linked to non-small cell lung carcinoma.